Stay updated on Dupilumab in Chronic Urticaria Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.

Latest updates to the Dupilumab in Chronic Urticaria Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record now presents details of the completed Phase 2 dupilumab study for chronic spontaneous urticaria, including its eligibility criteria, study locations, interventions, and outcome measures.SummaryDifference51%

- Check15 days agoChange DetectedThe 403 Forbidden message and its Home link disappeared, leaving the ClinicalTrials.gov page shell without visible study-record content. The site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check22 days agoChange DetectedA site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error page, replacing the previously visible study record details for NCT03749135. This indicates the study information is temporarily inaccessible due to an access restriction or site issue.SummaryDifference18%

Stay in the know with updates to Dupilumab in Chronic Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.